dark chocolate effect on cardiovascular side effect of diabetes

The effect of dark chocolate intake on serum nitric oxide, angiotensin? , adiponectin, inflammatory cytokines (IL-6? TNFa) and blood pressure in patients with type 2 diabetes.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015022116123N5

Enrollment

Registered

2015-03-11

Start date

2015-03-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus type 2. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention: diet controlling

30 gram of 84% dark chocolate per day, for two months. Intervention 2: control: diet controlling, for two months.

Treatment - Other

Intervention: diet controlling

30 gram of 84% dark chocolate per day, for two months

control: diet controlling, for two months

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: no food supplement consumption; body mass index 18.5-34.9; 30-60 years old; using only blood glucose reducing drugs, Metformin and Glibenclamide; willing to participate. Exclusion criteria: no appropriate corporation; any other disease; Obesity? (body mass index more than 34.9); pregnancy and lactating.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Nitric oxide. Timepoint: at the first and at the end of intervention period. Method of measurement: ELISA.;Adiponectin. Timepoint: at the first and at the end of intervention period. Method of measurement: ELISA.;Angiotensin?. Timepoint: at the first and at the end of intervention period. Method of measurement: ELISA.;Interleukine- 6. Timepoint: at the first and at the end of intervention period. Method of measurement: ELISA.;Tumor necrosis Factor-a. Timepoint: at the first and at the end of intervention period. Method of measurement: ELISA.;Blood pressure. Timepoint: at the first and at the end of intervention period. Method of measurement: Mercury sphygmomanometer.	—

Measure

Time frame

Nitric oxide. Timepoint: at the first and at the end of intervention period. Method of measurement: ELISA.;Adiponectin. Timepoint: at the first and at the end of intervention period. Method of measurement: ELISA.;Angiotensin?. Timepoint: at the first and at the end of intervention period. Method of measurement: ELISA.;Interleukine- 6. Timepoint: at the first and at the end of intervention period. Method of measurement: ELISA.;Tumor necrosis Factor-a. Timepoint: at the first and at the end of intervention period. Method of measurement: ELISA.;Blood pressure. Timepoint: at the first and at the end of intervention period. Method of measurement: Mercury sphygmomanometer.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026